| Literature DB >> 32612634 |
Edward Ryan-Moore1,2, Yiannis Mavrommatis1,3, Mark Waldron4,5.
Abstract
Background: Fractures are common in physically active populations and genetic differences may mediate injury risk. Objective: To meta-analyse the pooled results of candidate gene association studies with non-osteoporotic fracture risk in physically active humans.Entities:
Keywords: bone; fracture; human genetics; injury; intrinsic risk factors
Year: 2020 PMID: 32612634 PMCID: PMC7308497 DOI: 10.3389/fgene.2020.00551
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Meta-Analysis data input diagram. X, Risk Allele of genetic variant for fracture as defined by mechanistic rationale or candidate gene association study; Y, Non-Risk Allele of genetic variant. Symbols in parentheses indicate how the frequency counts were calculated to establish if differences in the risk allele distribution were present between cases and controls for each model.
Figure 2Genetic case-control association study of fracture risk in physically active participant systematic review and meta-analysis study selection process.
Summary of articles identified from systematic review of genetic case-control association studies with fracture risk in physically active participants.
| Blades et al. ( | M and F English Children presented to A&E following impact trauma | Fracture = 197-( | Recreational physical activity | Caucasian | |||
| Chatzipapas et al. ( | M only Military personnel | Stress Fracture = 32 | Military Duties | 23 ± 3 (19–30) | Unknown | ||
| Cosman et al. ( | M and F US Military Recruits | Stress Fracture = 69-( | Basic Military Training | M: 86.5% Caucasian, 5% Asian, 8.5% Black | No genetic association with stress fracture incidence ( | ||
| Korvala et al. ( | M only Finnish Military Conscripts | Stress Fracture = 72 | Basic Military Training | Unknown | Absence of CTR C allele and/or VDR C-A haplotype increased stress fracture risk ( | ||
| Suuriniemi et al. ( | F Finnish children | Fracture = 37 | 2.8–3.0 h/week | Unknown | COL1A2 P allele (either PP or Pp genotype) increased fracture risk compared to pp genotype ( | ||
| Välimäki et al. ( | M Finnish Military Conscripts | Stress Fracture = 15 | Basic Military Training | Unknown | No genetic association with stress fracture incidence ( | ||
| Varley et al. ( | M and F Elite Athletes from USA and UK (SFEA Cohort) | Stress Fracture = 125-( | Professional Athletes of Various Sports | Stress Fracture = 27.2 ± 6.9 | Caucasian: Stress Fractures 83.2%, Controls 79.9% | TNFSF11 rs1021188 AA ( | |
| Varley et al. ( | M and F Israeli Defence Force Soldiers and Elite Athletes from USA and UK (SFEA Cohort) | Military = 210-( | Military Training and Professional Athletes of Various Sports | Military: Stress Fracture = 20.3 ± 1.6, Control = 18.9 ± 0.5 | Elite Athletes: Stress fractures 83.2% Caucasian, 16.8% other. Controls 79.9%, Caucasian, 20.1% other | P2X7R rs1718119 A allele ( | |
| Varley et al. ( | M and F Elite Athletes from USA and UK (SFEA Cohort) | Stress Fracture = 125-( | Professional Athletes of Various Sports | Stress Fracture = 27.7 ± 7.5 | Caucasian: Stress Fractures 83.2%, Controls 79.9% | SOST rs1877632 TT+TC v CC ( | |
| Yanovich et al. ( | M and F Israeli Defence Force Soldiers | Stress Fracture = 182-( | Military Training | Stress Fracture = 20.1 ± 1.7 (18–32) | Ashkenazi 49.5%, Non-Ashkenazi 38.1%, and Unknown 12.4% | NR3C1, ANKH, VDR, ROR2, CALCR, IL6, CBG, and COL1A2 associated with increased risk of stress fracture ( | |
| Zhao et al. ( | M Chinese Military Recruits | Stress Fracture = 189 | Basic Military Training | Stress Fracture = 18.5 ± 1.4 | Unknown | GDF5 rs143383 T allele ( | |
M, male; F, female; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
Risk of bias assessment judgements for genetic case-control association studies with fracture risk in physically active participants.
| Blades et al. ( | Moderate | Serious | Moderate | Moderate | Low | Moderate | Serious |
| Chatzipapas et al. ( | Serious | Serious | Serious | Serious | Low | Moderate | Serious |
| Cosman et al. ( | Moderate | Moderate | Low | Low | Low | Moderate | Moderate |
| Korvala et al. ( | Serious | Serious | Serious | Serious | Moderate | Moderate | Serious |
| Suuriniemi et al. ( | Moderate | Moderate | Moderate | Moderate | Low | Moderate | Moderate |
| Välimäki et al. ( | Moderate | Moderate | Moderate | Moderate | Low | Moderate | Moderate |
| Varley et al. ( | Serious | Moderate | Low | Moderate | Low | Serious | Serious |
| Varley et al. ( | Serious | Serious | Serious | Moderate | Serious | Serious | Serious |
| Varley et al. ( | Serious | Serious | Serious | Moderate | Low | Serious | Serious |
| Yanovich et al. ( | Serious | Serious | Serious | Low | Serious | Critical | Critical |
| Zhao et al. ( | Moderate | Moderate | Low | Low | Low | Low | Moderate |
Figure 3Funnel plot of single nucleotide polymorphisms replicated in studies investigating genetic association with fracture risk in physically active participants using the allele contrast model.
Figure 5Funnel plot of single nucleotide polymorphisms replicated in studies investigating genetic association with fracture risk in physically active participants using the homozygote contrast model.
Summary effects from the overall analyses of case-control association studies for genetic variants associated with fracture occurrence risk in physically active participants including all studies and sex sub-groups.
| Allele Contrast: T | 772 (20%)/2514 (20%) | 4 | 17% | 0.30 | FE | 0.95 (0.76–1.19) | 0.66 | ||
| Recessive: TT+TG | 455 (32%)/1465 (31%) | 4 | 1% | 0.41 | 57% | 0.10 | FE | 0.99 (0.77–1.27) | 0.91 |
| Homozygote Contrast: TT | 455 (1.5%)/1465 (3%) | 4 | 0% | 0.70 | 0% | 0.63 | FE | 0.58 (0.25–1.32) | 0.19 |
| Allele Contrast: C | 342 (49%)/607 (51%) | 2 | RE | 1.81 (0.39–8.52) | 0.45 | ||||
| Recessive: CC+CA | 229 (62%)/393 (62%) | 2 | RE | 1.81 (0.46–7.17) | 0.40 | ||||
| Homozygote Contrast: CC | 229 (11%)/393 (16%) | 2 | RE | 0.87 (0.22–3.52) | 0.85 | ||||
| Allele Contrast: T | 313 (90%)/767 (88%) | 3 | 0% | 0.56 | 0% | 0.88 | FE | 1.27 (0.82–1.97) | 0.29 |
| Recessive: TT+TC | 189 (92%)/477 (91%) | 3 | 0% | 0.68 | 0% | 0.96 | FE | 1.23 (0.67–2.27) | 0.51 |
| Homozygote Contrast: TT | 189 (57%)/477 (51%) | 3 | 25% | 0.26 | 38% | 0.20 | RE | 1.23 (0.81–1.87) | 0.33 |
| Allele Contrast: C | 119 (76%)/1455 (73%) | 2 | 0% | 0.41 | 44% | 0.18 | FE | 1.25 (0.80–1.95) | 0.33 |
| Recessive: CC+CT | 80 (83%)/953 (79%) | 2 | 0% | 0.79 | 0% | 0.49 | FE | 1.28 (0.69–2.35) | 0.43 |
| Homozygote Contrast: CC | 80 (31%)/953 (32%) | 2 | 48% | 0.14 | RE | 0.92 (0.43–1.98) | 0.84 | ||
| Allele Contrast: G | 124 (89%)/1519 (86%) | 2 | 0% | 0.81 | RE | 1.02 (0.35–3.00) | 0.96 | ||
| Recessive: GG+GA | 80 (91%)/953 (90%) | 2 | 33% | 0.23 | 0% | 0.80 | RE | 1.11 (0.40–3.09) | 0.85 |
| Homozygote Contrast: GG | 80 (46%)/953 (49%) | 2 | 4% | 0.35 | 0% | 0.49 | FE | 0.91 (0.57–1.45) | 0.69 |
| Allele Contrast: T | 345 (14%)/863 (13%) | 2 | 0% | 0.92 | 0% | 0.99 | FE | 1.14 (0.78–1.65) | 0.50 |
| Recessive: TT+TC | 195 (24%)/481 (22%) | 2 | 0% | 0.94 | 0% | 0.89 | FE | 1.18 (0.78–1.77) | 0.43 |
| Homozygote Contrast: TT | 195 (1%)/481 (1.6%)* | 2* | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Allele Contrast: C | 342 (60%)/774 (48%) | 3 | 0% | 0.33 | RE | 1.60 (0.82–3.11) | 0.17 | ||
| Recessive: CC+CT | 220 (69%)/494 (61%) | 3 | 0% | 0.36 | RE | 1.49 (0.76–2.91) | 0.25 | ||
| Homozygote Contrast: CC | 220 (24%)/494 (16%) | 3 | 0% | 0.71 | 0% | 0.86 | FE | 1.49 (0.98–2.26) | 0.06 |
| Allele Contrast: C | 229 (71%)/588 (70%) | 2 | 0% | 0.83 | 0% | 0.66 | FE | 1.07 (0.76–1.51) | 0.71 |
| Recessive: CC+CA | 152 (78%)/387 (76%) | 2 | 0% | 0.89 | 0% | 0.91 | FE | 1.09 (0.68–1.73) | 0.72 |
| Homozygote Contrast: CC | 152 (29%)/387 (29%) | 2 | 11% | 0.32 | 43% | 0.19 | FE | 0.92 (0.60–1.41) | 0.70 |
| Allele Contrast: C | 332 (48%)/776 (48%) | 3 | 41% | 0.17 | 28% | 0.24 | RE | 1.05 (0.72–1.53) | 0.80 |
| Recessive: CC+CT | 218 (61%)/508 (60%) | 3 | 10% | 0.34 | 0% | 0.41 | FE | 1.01 (0.72–1.41) | 0.96 |
| Homozygote Contrast: CC | 218 (13%)/508 (13%) | 3 | 0% | 0.52 | 10% | 0.29 | FE | 0.98 (0.60–1.60) | 0.95 |
| Allele Contrast: T | 389 (62%)/2,002 (70%) | 4 | 47% | 0.09 | 0% | 0.54 | RE | 0.97 (0.68–1.39) | 0.87 |
| Recessive: TT+TG | 264 (72%)/1,306 (77%) | 4 | 0% | 0.50 | 0% | 0.90 | FE | 1.08 (0.79–1.49) | 0.62 |
| Homozygote Contrast: TT | 264 (19%)/1,306 (30%) | 4 | 25% | 0.25 | 0% | 0.94 | RE | 0.85 (0.60–1.21) | 0.37 |
RE, random effects; FE, fixed effects; OR, odds ratio; CI, confidence interval. Sample size describes frequency of case and control counts for each model with risk variant frequency in parentheses. *LRP5 (rs3736228) TT homozygotes present in only one of the two included studies. Values in bold indicate significant heterogeneity and/or associations with fracture risk.
Summary effects of case-control association studies for genetic variants associated with fracture occurrence risk in physically active females only.
| Allele Contrast: T | 92 (15%)/242 (26%) | 2 | 0% | 0.64 | FE | ||
| Recessive: TT+TG | 52 (25%)/144 (38%) | 2 | 0% | 0.49 | FE | 0.51 (0.24–1.06) | 0.07 |
| Homozygote Contrast: TT | 52 (2%)/144 (6%) | 2 | 0% | 0.53 | FE | 0.41 (0.07–2.33) | 0.31 |
| Allele Contrast: T | 76 (66%)/222 (70%) | 2 | 0% | 0.69 | FE | 1.13 (0.63–2.05) | 0.68 |
| Recessive: TT+TG | 51 (75%)/144 (77%) | 2 | 0% | 0.90 | FE | 1.14 (0.52–2.48) | 0.75 |
| Homozygote Contrast: TT | 51 (24%)/144 (31%) | 2 | 6% | 0.30 | FE | 0.87 (0.40–1.89) | 0.73 |
RE, random effects; FE, fixed effects; OR, odds ratio; CI, confidence interval. Sample size describes frequency of case and control counts for each model with risk variant frequency in parentheses. Values in bold indicate significant heterogeneity and/or associations with fracture risk.
Summary effects from the overall analyses of case-control association studies for genetic variants associated with fracture occurrence risk in physically active participants including only good and moderate quality studies with sex sub-groups.
| Allele Contrast: T | 561 (21%)/1,878 (21%) | 3 | 36% | 0.20 | 57% | 0.10 | RE | 0.95 (0.66–1.36) | 0.77 |
| Recessive: TT+TG | 333 (33%)/1,101 (33%) | 3 | 33% | 0.22 | 54% | 0.11 | RE | 0.96 (0.65–1.42) | 0.84 |
| Homozygote Contrast: TT | 333 (1.8%)/1,101 (3%) | 3 | 0% | 0.53 | 0% | 0.47 | FE | 0.73 (0.28–1.91) | 0.53 |
| Allele Contrast: T | 179 (68%)/1,405 (77%) | 2 | 41% | 0.18 | 0% | 0.93 | RE | 0.96 (0.59–1.56) | 0.87 |
| Recessive: TT+TG | 118 (75%)/915 (83%) | 2 | 0% | 0.45 | 0% | 0.90 | FE | 1.00 (0.62–1.62) | 1.00 |
| Homozygote Contrast: TT | 118 (27%)/915 (36%) | 2 | 0% | 0.39 | 0% | 0.45 | FE | 0.93 (0.59–1.47) | 0.75 |
RE, random effects; FE, fixed effects; OR, odds ratio; CI, confidence interval. Sample size describes frequency of case and control counts for each model with risk variant frequency in parentheses. Values in bold indicate significant heterogeneity and/or associations with fracture risk.
Summary effects of case-control association studies for genetic variants associated with fracture occurrence risk in physically active males only.
| Allele Contrast: T | 362 (17%)/1,960 (19%) | 3 | 0% | 0.99 | FE | 0.96 (0.70–1.31) | 0.80 |
| Recessive: TT+TG | 208 (28%)/1,138 (30%) | 3 | 0% | 0.93 | FE | 0.97 (0.68–1.37) | 0.85 |
| Homozygote Contrast: TT | 208 (2%)/1,138 (3%) | 3 | 0% | 0.43 | FE | 0.87 (0.28–2.70) | 0.81 |
| Allele Contrast: T | 271 (90%)/706 (89%) | 2 | 12% | 0.29 | FE | 1.27 (0.80–2.08) | 0.30 |
| Recessive: TT+TC | 163 (92%)/442 (91%) | 2 | 0% | 0.38 | FE | 1.22 (0.62–2.38) | 0.51 |
| Homozygote Contrast: TT | 163 (58%)/442 (51%) | 2 | 4% | 0.31 | FE | 1.35 (0.94–1.95) | 0.11 |
| Allele Contrast: C | 83 (81%)/1,294 (73%) | 2 | 0% | 0.99 | FE | 1.53 (0.80–2.91) | 0.14 |
| Recessive: CC+CT | 54 (85%)/849 (80%) | 2 | 0% | 0.96 | FE | 1.48 (0.69–3.20) | 0.32 |
| Homozygote Contrast: CC | 54 (39%)/849 (32%) | 2 | 48% | 0.14 | FE | 1.32 (0.75–2.32) | 0.34 |
| Allele Contrast: G | 85 (91%)/1,351 (87%) | 2 | RE | 0.92 (0.13–6.62) | 0.96 | ||
| Recessive: GG+GA | 54 (93%)/849 (90%) | 2 | 67% | 0.08 | RE | 0.96 (0.15–6.36) | 0.97 |
| Homozygote Contrast: GG | 54 (50%)/849 (44%) | 2 | 38% | 0.21 | RE | 0.93 (0.43–2.01) | 0.86 |
| Allele Contrast: T | 303 (12%)/798 (12%) | 2 | 0% | 0.69 | FE | 1.14 (0.75–1.72) | 0.54 |
| Recessive: TT+TC | 169 (21%)/443 (21%) | 2 | 0% | 0.73 | FE | 1.16 (0.75–1.81) | 0.50 |
| Homozygote Contrast: TT | 169 (0.6%)/443 (1.1%) | 2 | N/A | N/A | N/A | N/A | N/A |
| Allele Contrast: C | 304 (59%)/710 (49%) | 3 | RE | 1.42 (0.64–3.15) | 0.39 | ||
| Recessive: CC+CT | 194 (68%)/454 (60%) | 3 | RE | 1.32 (0.59–2.95) | 0.50 | ||
| Homozygote Contrast: CC | 194 (25%)/454 (17%) | 3 | 0% | 0.51 | FE | 1.47 (0.95–2.28) | 0.09 |
| Allele Contrast: C | 191 (71%)/531 (71%) | 2 | 0% | 0.68 | FE | 1.03 (0.71–1.50) | 0.86 |
| Recessive: CC+CA | 127 (78%)/347 (76%) | 2 | 0% | 0.64 | FE | 1.08 (0.65–1.78) | 0.78 |
| Homozygote Contrast: CC | 127 (28%)/347 (31%) | 2 | 0% | 0.47 | FE | 0.82 (0.52–1.30) | 0.40 |
| Allele Contrast: C | 295 (47%)/719 (48%) | 3 | 43% | 0.17 | RE | 0.96 (0.65–1.44) | 0.85 |
| Recessive: CC+CT | 193 (60%)/470 (60%) | 3 | 25% | 0.27 | RE | 0.96 (0.63–1.47) | 0.85 |
| Homozygote Contrast: CC | 193 (12%)/470 (13%) | 3 | 0% | 0.70 | FE | 0.90 (0.54–1.52) | 0.70 |
| Allele Contrast: T | 313 (61%)/1,780 (70%) | 4 | RE | 0.89 (0.54–1.48) | 0.65 | ||
| Recessive: TT+TG | 213 (71%)/1,162 (77%) | 4 | 30% | 0.23 | RE | 1.00 (0.64–1.56) | 0.98 |
| Homozygote Contrast: TT | 213 (18%)/1,162 (30%) | 4 | 47% | 0.13 | RE | 0.84 (0.47–1.50) | 0.54 |
RE, random effects; FE, fixed effects; OR, odds ratio; CI, confidence interval. Sample size describes frequency of case and control counts for each model with risk variant frequency in parentheses.
LRP5 (rs3736228) TT homozygotes present in only one of the two included studies. Values in bold indicate significant heterogeneity and/or associations with fracture risk.